Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172)

Paul Nathan*, Paolo A. Ascierto, John Haanen, Enrique Espinosa, Lev Demidov, Claus Garbe, Michele Guida, Paul Lorigan, Vanna Chiarion-Sileni, Helen Gogas, Michele Maio, Maria Teresa Fierro, Christoph Hoeller, Patrick Terheyden, Ralf Gutzmer, Tormod K. Guren, Dimitrios Bafaloukos, Piotr Rutkowski, Ruth Plummer, Ashita WaterstonMartin Kaatz, Mario Mandala, Ivan Marquez-Rodas, Eva Muñoz-Couselo, Reinhard Dummer, Elena Grigoryeva, Tina C. Young, Dirk Schadendorf

*Corresponding author for this work
    15 Citations (Scopus)

    Fingerprint

    Dive into the research topics of 'Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172)'. Together they form a unique fingerprint.

    Medicine & Life Sciences